Dalia Megiddo

Given Imaging Ltd. develops, manufactures, and markets diagnostic products and related medical monitoring equipment. Its solutions include capsule endoscopy, manometry, reflux monitoring and monometry. The company was founded by Gabi Iddan and Gavriel D. Meron in 1998 and is headquartered in Yokneam, Israel.

AngioScore LLC manufactures and wholesales angioplasty balloon catheters for the treatment of simple to complex coronary lesions. The firm designs, manufactures, and markets endovascular tools to treat cardiovascular and peripheral artery diseases. The company was founded by Gary Gershony, Nimrod Tzori, Tanhum Feld and Eitan Konstantino in 2003 and is headquartered in Colorado Springs, CO.

Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA.

VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.

Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel.

Impliant is engaged in the development of novel spine arthroplasty solutions for motion preservation. The Company's flagship device the TOPS Systems is a total posterior motion preservation system for patients suffering from mild to moderate spinal stenosis, with or without grade I spondylolisthesis and facet arthrosis. Impliant has the longest and largest series of patients for this indication with a motion preservation device. The Company's management team has extensive experience commercializing new technologies, including fusion and total disc replacement devices. Impliant raised its first round of venture capital investment in 2000 and remains a privately held company until today.